Römisch J, Gröner A, Bernhardt D, Diehl K H, Hein B, List W, Müller H G, Nowak T, Ronneberger H, Schüler E, Weimer T, Hilfenhaus J
Centeon Pharma GmbH, Marburg/Lahn, Deutschland.
Beitr Infusionsther Transfusionsmed. 1996;33:220-4.
For the manufacture of the PCC Beriplex P/N, nanofiltration was introduced into the production process of Beriplex HS providing an additional means to heat treatment for the clearance/inactivation of viruses. By nanofiltration, large enveloped viruses (HSV-1, HIV-1) were completely eliminated by a factor of more than 7 log10. While medium-sized enveloped viruses (HBV, BVDV) were cleared by a factor of approximately 4 log10, small non-enveloped viruses (poliovirus) were not removed. The product profile remained, no thrombogenic activities were detected.
为了生产凝血因子复合物百因止P/N,纳滤被引入到百因止HS的生产过程中,为病毒清除/灭活的热处理提供了额外手段。通过纳滤,大型包膜病毒(单纯疱疹病毒1型、人类免疫缺陷病毒1型)被完全清除,清除率超过7个对数级。中型包膜病毒(乙肝病毒、牛病毒性腹泻病毒)的清除率约为4个对数级,而小型无包膜病毒(脊髓灰质炎病毒)未被清除。产品特性保持不变,未检测到血栓形成活性。